Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189206 | 0.94 | OPRD1 (0.84) | OPRD1OPRM1KCNH2 | |
| SCHEMBL6191622 | 0.90 | OPRD1 (0.79) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6189184 | 0.89 | OPRD1 (0.76) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6190904 | 0.89 | OPRD1 (0.77) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL5778658 | 0.88 | OPRM1 (0.68) | OPRD1OPRM1KCNH2 | |
| SCHEMBL6191276 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6191397 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6191189 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL6191172 | 0.85 | OPRD1 (0.74) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL5781527 | 0.82 | OPRD1 (0.67) | OPRD1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286986-B1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | EP | claimed |
| US-6753335-B2 | DELTA AGONISTS FOR NERVOUS SYSTEM PAIN | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | claimed |
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | claimed |
| EP-1286986-B1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | EP | disclosed |
| US-6753335-B2 | DELTA AGONISTS FOR NERVOUS SYSTEM PAIN | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | disclosed |
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1286986-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001074806-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199548-A1 | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | OPRK1, OPRM1, OPRD1 | OPRD1 3/4885OPRM1 2/4885KCNH2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.